ClinicalTrials.gov
ClinicalTrials.gov Menu

MRI 3D UTE Hyper-Cones & ZTE for PET/MR Lung Attenuation Correction & for Lung Diagnostic Imaging

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03562806
Recruitment Status : Recruiting
First Posted : June 20, 2018
Last Update Posted : June 21, 2018
Sponsor:
Information provided by (Responsible Party):
University of Zurich

Brief Summary:
MRI 3D UTE Hyper-Cones & ZTE for PET/MR lung attenuation correction & for lung diagnostic imaging

Condition or disease Intervention/treatment Phase
Lung Diseases Diagnostic Test: PET/MR image acquisition Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: MRI 3D UTE Hyper-Cones & ZTE for PET/MR Lung Attenuation Correction & for Lung Diagnostic Imaging
Actual Study Start Date : May 23, 2018
Estimated Primary Completion Date : May 23, 2019
Estimated Study Completion Date : May 23, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: PET/MR (single arm)
PET and MR sequence acquisition on SIGNA PET/MR device
Diagnostic Test: PET/MR image acquisition
Acquisition of PET and MR sequences on SIGNA PET/MR device.




Primary Outcome Measures :
  1. Confirm that lung density map extraction is feasible through Hyper-Cones & ZTE scanning. [ Time Frame: 1 year ]
    Confirm that lung density map extraction is feasible through Hyper-Cones & ZTE scanning.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • informed consent and signature
  • clinical PET/CT planned and performed at Wagi site in Schlieren
  • male or female patients
  • from 18 to 80 years of age.

Exclusion Criteria:

- same exclusion criteria as for the clinical PET/CT exam (i.e. pregnant women).

Additional exclusion criteria:

- standard exclusion criteria for clinical MRI (evaluated by clinical standard determined by MRI questionnaire).


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03562806


Locations
Switzerland
University Hospital Zurich, Department of Nuclear Medicine Recruiting
Zurich, Switzerland, 8091
Contact: Martin Huellner, MD    0041442551111    martin.huellner@usz.ch   
Principal Investigator: Martin Huellner, MD         
Sponsors and Collaborators
University of Zurich

Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT03562806     History of Changes
Other Study ID Numbers: 2017-00899
First Posted: June 20, 2018    Key Record Dates
Last Update Posted: June 21, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases